As cell and gene therapy (CGT), vaccine development, and regenerative medicine advance, the demand for safe, stable, and scalable cell culture raw materials has never been greater. Recombinant human albumin (rHSA) — a cornerstone of serum-free, animal-free culture systems — is rapidly becoming an essential industry raw material. This article examines how domestically produced rHSA is powering the industrialization of cell therapy, from technology and quality to supply chain.

01 From Plasma to Recombinant: Animal-Free Is Now the Standard

Traditional cell culture depends on animal-derived serum and plasma proteins. But batch inconsistency, pathogen risk, and supply instability make them increasingly unsuitable for industrial use. Regulatory frameworks — including China’s "818" policy — now demand higher standards for raw material compliance, quality control, and animal-free origin.

What the cell industry requires from raw materials:

Safety — no viral or prion contamination, low immunogenicity

Traceability — clear raw material provenance, GMP-compliant production

Batch stability — consistent performance across every batch

Scalable supply — reliable delivery from R&D through commercial production

In this environment, chemically defined, animal-free culture media have become the consensus. Recombinant human albumin — precisely defined, non-animal-derived — is the natural replacement for plasma albumin in serum-free systems.

02 Technical Foundation: Pichia Pastoris Expression

Anrate produces rHSA using a mature recombinant *Pichia pastoris* expression system — a well-established biopharmaceutical platform offering high expression efficiency, high-density fermentation capability, and manageable production costs.

Core advantages of Pichia-derived rHSA:

Animal-free — eliminates viral and prion contamination risk at the source

High purity, high consistency — standardized fermentation and multi-step purification deliver >99% purity with minimal batch-to-batch variation

Structurally native— molecular structure is near-identical to liver-produced human albumin, preserving full biological function including osmotic pressure maintenance and nutrient transport

03 Commercial Readiness: Capacity Meets Clinical Validation

For cell therapy companies entering industrialization, supply chain reliability decides commercial success.

Anrate’s 50-ton annual rHSA capacity signals that large-scale domestic supply of this critical raw material is now a reality. Equally important, the product has passed the highest bar of clinical scrutiny: Anrate’s rHSA injection is approved for marketing in Russia and Kyrgyzstan and has completed Phase III clinical trials in China — proof of safety and efficacy as both pharmaceutical excipient and drug substance.

Key applications across the cell industry:

Cell and gene therapy — protects CAR-T, NK, and stem cells from shear stress; enhances nutrient delivery and expansion efficiency

Vaccine production — stabilizes antigens in viral and recombinant protein vaccine manufacturing

Serum-free media development — replaces serum albumin as a core functional component in chemically defined, customizable media

Biopharmaceuticals — serves as a stabilizer and excipient in recombinant protein drug formulation, extending shelf life

Compared to imported alternatives, domestic rHSA offers clear advantages in supply stability, lead time, and cost — helping Chinese biopharma companies reduce production costs and reach the market faster.

04 Conclusion

Cell therapy is moving from the lab to the factory floor. Safe, stable, scalable recombinant proteins — rHSA above all — are now core infrastructure for this transformation. By mastering recombinant expression and industrial-scale production, and by validating product quality through successful clinical trials and international approvals, companies like Anrate are breaking the import monopoly on critical biological raw materials and building a self-reliant foundation for the future of China’s biopharmaceutical industry.

05 About Us

SciProTech is the protein reagent brand of SciProMed, an Anrate company. 

Built on proprietary platforms for high-efficiency recombinant protein expression, large-scale fermentation, and purification, SciProTech supplies animal-free recombinant protein raw materials at industrial scale to biotechnology and life science companies worldwide.

Products: recombinant human albumin, transferrin, insulin, trypsin, growth factors, interleukins, ECM proteins, and monoclonal antibodies — all manufactured under strict quality control for batch-to-batch consistency.

Services: full-species antibody discovery CRO spanning phage display, yeast display, and protein engineering platforms.

50-ton annual capacity. Clinically validated. Trusted across CGT, biopharma, and vaccine manufacturing.